Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Invested Capital (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Invested Capital data on record, last reported at $730.0 million in Q4 2025.

  • For Q4 2025, Invested Capital changed N/A year-over-year to $730.0 million; the TTM value through Dec 2025 reached $730.0 million, changed N/A, while the annual FY2025 figure was $730.0 million, N/A changed from the prior year.
  • Invested Capital reached $730.0 million in Q4 2025 per RCUS's latest filing, up from $534.0 million in the prior quarter.
  • Across five years, Invested Capital topped out at $842.0 million in Q4 2021 and bottomed at $462.0 million in Q4 2023.
  • Average Invested Capital over 5 years is $639.2 million, with a median of $635.0 million recorded in 2024.
  • Peak YoY movement for Invested Capital: soared 372.7% in 2021, then dropped 29.68% in 2023.
  • A 5-year view of Invested Capital shows it stood at $842.0 million in 2021, then decreased by 21.97% to $657.0 million in 2022, then fell by 29.68% to $462.0 million in 2023, then soared by 32.47% to $612.0 million in 2024, then increased by 19.28% to $730.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Invested Capital were $730.0 million in Q4 2025, $534.0 million in Q3 2025, and $646.0 million in Q2 2025.